Organization | Centro Medico Nacional La Raza, IMSS

Centro Medico Nacional La Raza, IMSS Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial

2017

NCT03877120

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Alternative names

Centro Medico Nacional La Raza, IMSS | Hematology Department La Raza Medical Center | Hospital General, Centro Médico Nacional "La Raza", IMSS | La Raza Medical Center

Active Ingredients

Drugs in Phase 4 Trials (5)

dexmedetomidine (precedex) (1 trial)

diazepam (valium) (1 trial)

insulin glargine (toujeo) (1 trial)

insulin lispro (humalog) (1 trial)

sitagliptin (januvia) (1 trial)

Drugs in Phase 2 Trials (5)

carboplatin (paraplatin) (1 trial)

cytarabine (cytosar-u) (1 trial)

dexamethasone (1 trial)

filgrastim (neupogen) (1 trial)

rituximab (rituxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alcohol Withdrawal Delirium (Phase 4)

Delirium (Phase 4)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Substance Withdrawal Syndrome (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial APIs: 10